Msd Sub Merck Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MSD SUB MERCK, and what generic alternatives to MSD SUB MERCK drugs are available?
MSD SUB MERCK has fourteen approved drugs.
There are twenty US patents protecting MSD SUB MERCK drugs.
There are five hundred and forty-nine patent family members on MSD SUB MERCK drugs in sixty countries and one hundred and fifty-eight supplementary protection certificates in nineteen countries.
Summary for Msd Sub Merck
International Patents: | 549 |
US Patents: | 20 |
Tradenames: | 13 |
Ingredients: | 11 |
NDAs: | 14 |
Drugs and US Patents for Msd Sub Merck
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Msd Sub Merck | ISENTRESS HD | raltegravir potassium | TABLET;ORAL | 022145-002 | May 26, 2017 | RX | Yes | Yes | 8,771,733 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
Msd Sub Merck | JANUMET | metformin hydrochloride; sitagliptin phosphate | TABLET;ORAL | 022044-002 | Mar 30, 2007 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
Msd Sub Merck | ZEPATIER | elbasvir; grazoprevir | TABLET;ORAL | 208261-001 | Jan 28, 2016 | RX | Yes | Yes | 7,973,040 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Msd Sub Merck
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Msd Sub Merck | INTEGRILIN | eptifibatide | INJECTABLE;INJECTION | 020718-002 | May 18, 1998 | 5,686,570 | ⤷ Subscribe |
Msd Sub Merck | STEGLUJAN | ertugliflozin; sitagliptin phosphate | TABLET;ORAL | 209805-001 | Dec 19, 2017 | 7,459,428 | ⤷ Subscribe |
Msd Sub Merck | STEGLUJAN | ertugliflozin; sitagliptin phosphate | TABLET;ORAL | 209805-002 | Dec 19, 2017 | 6,890,898 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MSD SUB MERCK drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 2 mg/mL, 100 mL vial | ➤ Subscribe | 2008-12-18 |
➤ Subscribe | Injection | 1 g/vial | ➤ Subscribe | 2013-06-20 |
➤ Subscribe | Ophthalmic Solution | 2% | ➤ Subscribe | 2005-10-11 |
➤ Subscribe | Extended-release Tablets | 100 mg/1000 mg | ➤ Subscribe | 2012-10-22 |
➤ Subscribe | Injection | 2 mg/mL, 10 mL vial | ➤ Subscribe | 2008-09-30 |
➤ Subscribe | Injection | 0.75 mg/mL, 100 mL vial | ➤ Subscribe | 2009-06-05 |
➤ Subscribe | Tablets | 400 mg | ➤ Subscribe | 2011-10-12 |
➤ Subscribe | Extended-release Capsules | 50 mg/500 mg and 50 mg/1000 mg | ➤ Subscribe | 2012-03-16 |
➤ Subscribe | Tablets | 50 mg/500 mg and 50 mg/1000 mg | ➤ Subscribe | 2010-10-18 |
International Patents for Msd Sub Merck Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Costa Rica | 20120289 | ⤷ Subscribe |
Hong Kong | 1156616 | ⤷ Subscribe |
New Zealand | 560485 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Msd Sub Merck Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2310095 | LUC00002 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: GRAZOPREVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI / ZEPATIER - ELBASVIR/GRAZOPREVIR; AUTHORISATION NUMBER AND DATE: EU/1/16/1119 |
2410844 | PA2016048,C2410844 | Lithuania | ⤷ Subscribe | PRODUCT NAME: ELBASVIRAS ARBA JO FARMACISKAI PRIIMTINOS DRUSKOS; REGISTRATION NO/DATE: EU/1/16/1119 20160722 |
2334687 | PA2018510 | Lithuania | ⤷ Subscribe | PRODUCT NAME: ERTUGLIFLOZINAS, PASIRINKTINAI KAIP KRISTALINE FORMA, YPAC KAIP KO-KRISTALAS SU L-PIROGLUTAMO RUGSTIMI, IR YPAC KAIP ERTUGLIFLOZINO L-PIROGLUTAMO RUGSTIS; REGISTRATION NO/DATE: EU/1/18/1267 20180321 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.